View Post

Non-traditional gene fusions in luminal breast cancer: A new target for therapy

In In The News by Barbara Jacoby

Source: Oncotarget From: A new editorial paper was published in Oncotarget’s Volume 14 on June 12, 2023, entitled, “Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?” A vast majority of breast cancers (~70%) are estrogen receptor-alpha positive (ER+), for which endocrine therapy is the common treatment. However, recurrence often occurs leading to tumor progression, metastasis and …